Thursday, November 19, 2026

DD India

Top Stories of the Day

November 19, 2026 12:48 PM IST

New Drugs and Clinical Trials Rules 2019 | NDCT Rules Amendment | Antimicrobial Regulation | Central Regulatory Oversight | Union Health Ministry | Antimicrobial resistance | AMR | Health Ministry India

Health Ministry Proposes Amendment to Drug Rules to Bring Antimicrobials Under Central Regulatory Oversight

Miscellaneous Drugs (Photo By BSIP/UIG Via Getty Images)

The Union Ministry of Health and Family Welfare has proposed amendments to the New Drugs and Clinical Trials Rules, 2019, to bring antimicrobials under the regulatory framework applicable to new drugs, strengthening oversight and addressing the growing challenge of antimicrobial resistance (AMR).

The proposed amendment, outlined in draft Gazette Notification G.S.R. 983(E) dated November 6, seeks to include ‘antimicrobials’ in the definition of ‘New Drug’ under Rule 2(1)(w)(v) of the rules.

Antimicrobial resistance is a major global public health concern requiring coordinated action. The G20 New Delhi Leaders’ Declaration had also emphasised the need to address AMR through a One Health approach.

According to the ministry, the proposed amendment follows concerns over the grant of manufacturing licences for antimicrobial products without adequate regulatory scrutiny, including assessments such as bioavailability and bioequivalence studies and stability studies.

The absence of such assessments could compromise the quality, safety and efficacy of antimicrobial products. Substandard or ineffective antimicrobials may also contribute to the emergence and spread of antimicrobial resistance, posing risks to patient safety.

Under the proposed framework, manufacturers would be required to obtain prior permission from the Central Licensing Authority (CLA) before applying to the concerned State Licensing Authority (SLA) for a manufacturing licence.

The move is aimed at strengthening central regulatory oversight and ensuring that antimicrobial products meet the required standards of quality, safety and efficacy.

The draft notification has been issued to invite objections and suggestions from stakeholders and members of the public before the Central Government considers finalising the proposed amendment.

Objections and suggestions may be submitted to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, U-6, Work Hall–C Wing, First Floor, Kartavya Bhawan-1, New Delhi–110001, or emailed to drugsdiv-mohfw[at]gov[dot]in.

Submissions must be made within 30 days from the date on which copies of the Gazette containing the draft rules are made available to the public.

(PIB)

Last updated on: 19th November 2026

Back to top